www.profil-research.de Gehe zur Webseite
Profil GmbH Answers for Diabetes
Eingehende Links: | 12 |
Sprache/Land: | EN |
Webseiten Geschwindigkeit: | 0.077 Sekunden |
Kein Besucheraufkommen zu dieser Domain gefunden.
Wichtigste Keywords
Profil Profil Institut DIABETES DIABETES SCI TECHNOL Scientific Diabetes Research Publications Veresiu IA Recent Publications type diabetes DIABETES OBES METAB print DIABETES STOFFWECHSEL gespeicherten Daten personenbezogenen Daten Haftung Auskunft Berichtigung Sperrung EXP CLIN ENDOCRINOL continuous glucose monitoring Smith SM Heer CCM BugaGloede Friends Cookies Links Inhalte factor Mader JK insulin glargine insulin degludec Wardlaw SL PLoS One Epub ahead allgemeinen Gesetzen unbefugten Zugriff verlinkten Seiten glucose-lowering effect basal insulin Heise Veresiu IA Tschoepe D. Kapitza Heinemann bone Zwart Nosek patients Stirban Einwilligung induced daily Rechtsverletzungen umgehend
Serverdaten
Serverstandort: Erkrath in Deutschland
Die IP-Adresse lautet 213.218.167.165.
DNS-Daten
Host | Klasse | Typ | Ziel |
---|---|---|---|
profil-research.de | IN | MX | mail.profil-research.de |
profil-research.de | IN | MX | fbmail.profil-research.de |
profil-research.de | IN | MX | email.securewebs.net |
profil-research.de | IN | SOA | ns1.securewebs.net |
profil-research.de | IN | NS | ns2.securewebs.net |
profil-research.de | IN | NS | ns1.securewebs.net |
profil-research.de | IN | A | 213.218.167.165 |
Server-Ping
PING profil-research.de (213.218.167.165) 56(84) bytes of data. --- profil-research.de ping statistics --- 97 packets transmitted, 0 received, 100% packet loss, time 19951ms
Die Seite hat eine Ladezeit von 0.077 Sekunden.
HTTP-Header
HTTP-Tag | Wert |
---|---|
http_version | HTTP/1.1 |
statuscode | 200 |
date | Thu, 24 Jul 2014 12:23:03 GMT |
server | Apache/2.2.3 (CentOS) |
last-modified | Tue, 15 Jul 2014 15:30:21 GMT |
etag | "88000b-aa43-15ea9d40" |
accept-ranges | bytes |
content-length | 43587 |
connection | close |
content-type | text/html; charset=UTF-8 |
Meta Tags
Meta-Tag | Wert |
---|---|
description | |
author | |
X-UA-Compatible | IE=edge,chrome=1 |
charset | utf-8 |
Interne Links
Anchor | URL |
---|
Externe Links
Anchor | URL |
---|---|
Studienteilnahme | http://www.profil.de |
www.bugagloede.de | http://www.bugagloede.de |
www.fotolia.com | http://www.fotolia.com |
Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 week´s treatment with empagliflozin once daily in patients with type 2 diabetes. | http://www.ncbi.nlm.nih.gov/pubmed/23356556 |
Pharmacodynamic characteristics of lixisenatide once daily vs liraglutide once daily in patients with type 2 diabetes insufficiently controlled on metformin. | http://www.ncbi.nlm.nih.gov/pubmed/23368510 |
Insulin aspart has a shorter duration of action than human insulin over a wide dose-range. | http://www.ncbi.nlm.nih.gov/pubmed/22882249 |
How do patients' Exp Clin Endocrinol Diabetespreferences compare to the present spectrum of diabetes research? | http://www.ncbi.nlm.nih.gov/pubmed/22972031 |
Continuous glucose monitoring: quality of hypoglycaemia detection. | http://www.ncbi.nlm.nih.gov/pubmed/22974231 |
Plasma exposure to insulin glargine and its metabolites M1 and M2 after subcutaneous injection of therapeutic and supratherapeutic doses of glargine in subjects with type 1 diabetes. | http://www.ncbi.nlm.nih.gov/pubmed/23093664 |
Alkaline salts to counteract bone resorption and protein wasting induced by high salt intake: Results of a randomized controlled trial. | http://www.ncbi.nlm.nih.gov/pubmed/23027921 |
Ähnliche Domains
Letzte Aktualisierung: 24.07.2014 14:59